Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Hamilton Thorne Ltd HTLZF

Hamilton Thorne Ltd. is a provider of precision instruments, consumables, software and services to assisted reproductive technologies (ART), research, and cell biology markets. The Company markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, and Embryotech Laboratories brands. It also provides an array of third-party equipment and... see more

OTCPK:HTLZF - Post Discussion

Hamilton Thorne Ltd > small cap news lag?
View:
Post by Possibleidiot01 on Aug 18, 2021 5:08pm

small cap news lag?

Considering these highlights , I'm a little surprised that the stock did nothing.

Highlights

  • Sales increased 71% year over year to $12.5 million for the quarter; sales for the six-month period increased 36% to $24 million; constant currency increase of 62% for the quarter and 29% for the six-month period
  • Gross profit increased 69% to $6.4 million for the quarter; increased 36% to $12.3 million for the six-month period
  • Net income was $482 thousand for the quarter and $1.35 million for the six-month period, versus net losses of $594 thousand and $449 thousand in the prior year periods
  • Adjusted EBITDA increased 334% to $2.45 million for the quarter and 99% to $4.77 million for the six-month period
  • Organic growth in USD was 70%, 61% in constant currency; 35% organic growth for the six-month period, 29% in constant currency
  • Cash generated from operations was $1.7 million for the quarter, and $3.2 million for the six-month period; total cash on hand at June 30, 2021 was $20.6 million
Maybe this news was already baked into the price? If the stock achieves $50 million USD - that would be $200 million USD more or less - 4x sales.
GLTA
Comment by Jamie2 on Aug 19, 2021 10:40am
Got a new buy rating today from Colliers Securities at $2.53
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities